• Vaccine Name: P. falciparum LSA-3 Protein Vaccine
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Vaccine Ontology ID: VO_0004193
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant proteins GST-DG729, GST-NN and GST-PC were designed to cover 95% of the LSA-3 antigen and were used as a mixture (called LSA-3 GST-rec) (Daubersies et al., 2000).
• LSA-3 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001270
  • Description: Montanide ISA51
• Immunization Route: subcutaneous injection

Chimpanzee Response

• Vaccination Protocol: 50 μg of recombinant LSA-3 peptides were emulsified in Montanide ISA51 and were injected subcutaneously into chimpanzees (Daubersies et al., 2000).
• Challenge Protocol: All chimpanzees were immunized at weeks 0, 4 and 8 and were challenged with 2 x 10^4 sporozoites at week 13 (Daubersies et al., 2000).
• Efficacy: Immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites (Daubersies et al., 2000).